



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - WO66-G609  
Silver Spring, MD 20993-0002

January 16, 2015

Boston Scientific Corporation  
Carter Navarro  
Manager, Regulatory Affairs  
100 Boston Scientific Way  
Mail Stop M-11  
Marlborough, MA 01752

Re: K142922  
Trade/Device Name: SpyGlass DS Direct Visualization System  
Regulation Number: 21 CFR 876.1500  
Regulation Name: Gastroenterology/Urology  
Regulatory Class: Class II  
Product Code: FBN, NTN, KQM  
Dated: December 19, 2014  
Received: December 22, 2014

Dear Carter Navarro,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the [Federal Register](#).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-

related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

**Benjamin R. Fisher -A**

Benjamin R. Fisher, Ph.D.  
Director  
Division of Reproductive, Gastro-Renal,  
and Urological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Food and Drug Administration

Form Approved: OMB No. 0910-0120  
Expiration Date: January 31, 2017  
See PRA Statement below.

## Indications for Use

510(k) Number (if known)

K142922

Device Name

SpyGlass DS Direct Visualization System

Indications for Use (Describe)

The SpyGlass DS Direct Visualization System is indicated for use in diagnostic and therapeutic applications during endoscopic procedures in the pancreatico-biliary system including the hepatic ducts.

The SpyGlass DS Direct Visualization System comprises two components: the SpyScope DS Access and Delivery Catheter and the SpyGlass DS Digital Controller.

The SpyScope DS Access and Delivery Catheter is intended to provide direct visualization and to guide both optical and accessory devices for diagnostic and therapeutic applications during endoscopic procedures in the pancreatico-biliary system including the hepatic ducts.

The SpyGlass DS Digital Controller is intended to provide illumination and receive, process, and output images from the SpyScope DS Access and Delivery Catheter for diagnostic and therapeutic applications during endoscopic procedures in the pancreatico-biliary system including the hepatic ducts.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
PRAStaff@fda.hhs.gov

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*



Boston Scientific Corporation  
 300 Boston Scientific Way  
 Marlborough, MA 01752  
 (508) 382-4000  
[www.bostonscientific.com](http://www.bostonscientific.com)

## 510(k) Summary for SpyGlass™ DS Direct Visualization System

### 1. Submitter

Boston Scientific Corporation  
 Endoscopy Division  
 100 Boston Scientific Way  
 Marlborough, MA 01752

**Contact:** Carter Navarro  
 Manager, Regulatory Affairs  
 Phone: (508) 683-4793  
 Fax: (508) 683-5939  
 E-mail: [carter.navarro@bsci.com](mailto:carter.navarro@bsci.com)

Date Prepared: October 7, 2014

### 2. Device

Trade Name: SpyGlass DS Direct Visualization System  
 Common Name: Choledochoscope and accessories, flexible/rigid;  
 Surgical camera and accessories; LED light source  
 Product Code: FBN, KQM, NTN  
 Device Class and Panel: Class II, Gastroenterology/Urology (FBN, NTN)  
 Class I, General and plastic surgery (KQM)  
 Classification Regulation: 21 CFR 876.1500 (FBN, NTN)  
 21 CFR 878.4160 (KQM)

### 3. Predicate Devices

Trade Name: ACMI DUR-Digital Ureteroscope and  
 Choledochoscope System  
 Manufacturer: ACMI Corporation  
 Clearance Number: K060269  
 Common Name: Choledochoscope and accessories, flexible/rigid  
 Product Code: FBN  
 Device Class and Panel: Class II, Gastroenterology/Urology  
 Classification Regulation: 21 CFR 876.1500

Trade Name: SpyScope Access and Delivery Catheter  
 Manufacturer: Boston Scientific Corporation  
 Clearance Number: K090170

Common Name: Mini endoscope, gastroenterology-urology  
 Product Code: ODF  
 Device Class and Panel: Class II, Gastroenterology/Urology  
 Classification Regulation: 21 CFR 876.1500

Trade Name: SpyGlass Direct Visualization Probe/Ocular  
 Manufacturer: Boston Scientific Corporation  
 Clearance Number: K052194  
 Common Name: Endoscope and/or accessories  
 Product Code: KOG  
 Device Class and Panel: Class II, Gastroenterology/Urology  
 Classification Regulation: 21 CFR 876.1500

Trade Name: Olympus XCHF-B180Y1 Choledochoscope  
 Manufacturer: Olympus Medical Systems Corporation  
 Clearance Number: K080586  
 Common Name: Choledochoscope and accessories, flexible/rigid  
 Product Code: FBN  
 Device Class and Panel: Class II, Gastroenterology/Urology  
 Classification Regulation: 21 CFR 876.1500

Trade Name: Stryker LED Light Source  
 Manufacturer: Stryker Endoscopy  
 Clearance Number: K082813  
 Common Name: Light source, fiberoptic, routine  
 Product Code: FCW  
 Device Class and Panel: Class II, Gastroenterology/Urology  
 Classification Regulation: 21 CFR 876.1500

#### 4. Device Description

The SpyGlass DS Direct Visualization System comprises two components: (1) the sterile, single-use SpyScope DS Access and Delivery Catheter (“Catheter”) and (2) the SpyGlass DS Digital Controller (the “Controller”).

The Catheter is a flexible video cholangiopancreatroscope, introduced into the pancreatico-biliary system via a duodenoscope. The Catheter comprises a handle, an insertion tube, and a connection cable. The handle includes two articulation control knobs, a lever to lock the control knobs in place, connectors for irrigation and aspiration, a working channel port, and a strap to attach the Catheter to a duodenoscope. The insertion tube contains one working channel for accessory devices and aspiration, two channels for irrigation, two optical fibers to transmit illumination from the Controller, and wiring to transmit video signals to the Controller. The bending section at the distal portion of the insertion tube is controlled by the user via the articulation control knobs on the handle. The distal end of the insertion tube contains an imaging sensor for capturing

video and transmitting it to the Controller, elements for transmitting illumination from the Controller, and the distal openings of the irrigation and working channels. The connection cable connects the Catheter handle to the Controller for transmitting illumination and video signals.

The Controller is an endoscopic video imaging system that combines the functionality of a camera and an LED light source. The Controller receives video signals from the Catheter, processes the video signals, and outputs video images to an attached monitor. The Controller also generates and controls the illumination transmitted to the distal end of the Catheter. The user interface of the Controller comprises a power button, a receptacle to connect the Catheter connection cable, buttons to turn illumination on or off and to control the illumination intensity, and an illumination intensity indicator. The Controller outputs video images to an attached monitor via DVI, VGA, or S-Video ports, and the user may select NTSC or PAL video formats according to the geographic region of use.

## **5. Indication for Use**

The SpyGlass DS Direct Visualization System is indicated for use in diagnostic and therapeutic applications during endoscopic procedures in the pancreatobiliary system including the hepatic ducts.

The SpyGlass DS Direct Visualization System comprises two components: the SpyScope DS Access and Delivery Catheter and the SpyGlass DS Digital Controller.

The SpyScope DS Access and Delivery Catheter is intended to provide direct visualization and to guide both optical and accessory devices for diagnostic and therapeutic applications during endoscopic procedures in the pancreatobiliary system including the hepatic ducts.

The SpyGlass DS Digital Controller is intended to provide illumination and receive, process, and output images from the SpyScope DS Access and Delivery Catheter for diagnostic and therapeutic applications during endoscopic procedures in the pancreatobiliary system including the hepatic ducts.

## **6. Technological Characteristics**

The proposed SpyGlass DS Direct Visualization System shares similar design features and functions with the predicate devices.

The proposed device and predicate ACMI DUR-Digital Ureteroscope and Cholecholescope System share similar indications for use, both being intended for use for examination of the bile duct, and facilitating diagnostic and therapeutic procedures in the bile duct. The proposed device and predicate ACMI DUR-Digital Ureteroscope and

Choledochoscope System share similar technological characteristics, including CMOS image sensors for visualization, light-emitting diodes (LEDs) for illumination (the light source is located in the handheld component of the predicate device), and similar video output capabilities. The differences in respect to the dimensions of the Catheter and location of the LEDs do not alter the suitability of the proposed device for its intended use.

In overall appearance, dimensions, and mechanical performance, the proposed SpyScope DS Access and Delivery Catheter is very similar to the SpyScope Access and Delivery Catheter, while adding the optical functionality of the SpyGlass Probe/Ocular. The minor dimensional differences between the proposed SpyScope DS Access and Delivery Catheter and the predicate SpyScope Access and Delivery Catheter do not raise new questions of safety or effectiveness for the proposed device's intended use in the pancreatico-biliary system. The applicable dimensions are within the range of the predicate Olympus XCHF-B180Y1 Choledochoscope, which has the same indications for use.

The proposed SpyGlass DS Digital Controller and the predicate Stryker LED Light Source share similar technological characteristics, both utilizing LEDs for illumination, and both offering brightness control.

## 7. Substantial Equivalence

A direct comparison of key characteristics demonstrates that the SpyGlass DS Direct Visualization System is substantially equivalent to the predicate devices in terms of intended use, technological characteristics, and performance characteristics. The SpyGlass DS Direct Visualization System is as safe and effective as the predicate devices.

## 8. Performance Data

Non-clinical testing was successfully performed on the proposed SpyGlass DS Direct Visualization System.

Performance testing (bench) was successfully completed to establish substantial equivalence between the proposed SpyGlass DS Direct Visualization System and the predicate devices. This testing included the following:

- Diameter
- Working length
- Working channel diameter
- Field of view
- Direction of view
- Resolution
- Articulation direction
- Articulation angle
- Surface and edges
- Irrigation and working channel system leakage
- Articulation reliability
- Attachment to duodenoscope reliability
- Duodenoscope compatibility

- Irrigation pump compatibility
- Accessory compatibility
- Image noise
- Video latency
- System frame rate
- Illumination intensity
- Default automatic light control setpoint
- Automatic light control response time
- Simultaneous video output

Biocompatibility of the SpyScope DS Access and Delivery Catheter was evaluated in accordance with ISO 10993-1:2009 for the body contact category of “surface – mucosal membrane” with a contact duration of “limited ( $\leq 24$  hours),” and the following tests were performed: Cytotoxicity, Irritation, Sensitization, USP Physiochemical <661>, and Latex. All evaluation acceptance criteria were met.

Electrical safety and electromagnetic compatibility of the SpyGlass DS Direct Visualization System were evaluated in accordance with IEC 60601-1:2005 + CORR. 1:2006 + CORR. 2:2007 + AM1:2012, IEC 60601-1-2:2007, and IEC 60601-2-18:2009. All evaluation acceptance criteria were met.

The results of non-clinical testing demonstrate that the SpyGlass DS Direct Visualization System is considered safe and effective for its intended use.

## 9. Conclusion

Boston Scientific has demonstrated that the proposed SpyGlass DS Direct Visualization System is substantially equivalent to the currently marketed predicate devices.